New biotech company Complement Therapeutics has been launched with big ambitions to develop a gene therapy for millions of patients who suffer from the eye condition geographic atrophy (GA), led by a CEO who had a hand in building the two biggest ophthalmology blockbusters.
The UK company has emerged from stealth mode with a relatively modest €5m in seed funding from European venture capital...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?